Dark Forest Capital Management LP Takes $441,000 Position in RxSight, Inc. (NASDAQ:RXST)

Dark Forest Capital Management LP bought a new position in RxSight, Inc. (NASDAQ:RXST) in the fourth quarter, Holdings Channel reports. The firm bought 12,815 shares of the company’s stock, valued at approximately $441,000.

A number of other institutional investors also recently bought and sold shares of the stock. DF Dent & Co. Inc. purchased a new position in shares of RxSight in the fourth quarter worth $14,524,000. Artisan Partners Limited Partnership raised its stake in RxSight by 32.6% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company’s stock worth $53,345,000 after acquiring an additional 381,389 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in RxSight by 196.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 359,144 shares of the company’s stock worth $12,346,000 after acquiring an additional 237,877 shares during the period. Renaissance Technologies LLC grew its stake in RxSight by 102.9% during the 4th quarter. Renaissance Technologies LLC now owns 361,500 shares of the company’s stock valued at $12,428,000 after purchasing an additional 183,300 shares during the last quarter. Finally, Altium Capital Management LLC increased its holdings in shares of RxSight by 154.5% in the fourth quarter. Altium Capital Management LLC now owns 285,000 shares of the company’s stock valued at $9,798,000 after purchasing an additional 173,000 shares during the period. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RXST has been the subject of a number of research reports. Bank of America reaffirmed an “underperform” rating and set a $22.00 target price (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. UBS Group downgraded shares of RxSight from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $45.00 to $16.00 in a report on Wednesday, April 9th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research note on Thursday, April 3rd. Stifel Nicolaus decreased their target price on shares of RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Finally, Piper Sandler started coverage on RxSight in a research report on Tuesday, April 15th. They set a “neutral” rating and a $18.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $37.60.

Insider Buying and Selling at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. The trade was a 22.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.36% of the company’s stock.

RxSight Stock Up 1.5 %

NASDAQ:RXST opened at $14.95 on Friday. RxSight, Inc. has a 52 week low of $13.50 and a 52 week high of $66.54. The stock’s 50-day moving average price is $22.14 and its 200-day moving average price is $33.86. The stock has a market capitalization of $607.27 million, a PE ratio of -18.01 and a beta of 1.26.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business had revenue of $40.21 million during the quarter, compared to analysts’ expectations of $40.23 million. Sell-side analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.